Pasar al contenido principal

-

RYC-2012-11873

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Contratación e Incorporación de RRHH
Subprograma Subprograma Ramón y Cajal (RYC)
Convocatoria Ramón y Cajal
Año convocatoria 2012
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vestibular CCK signaling drives motion sickness-like behavior in mice

  • Machuca Márquez, Pablo|||0000-0002-7980-3839
  • Sánchez Benito, Laura
  • Menardy, Fabien Louis Joseph|||0000-0002-8712-1344
  • Urpi, Andrea|||0000-0002-2437-7094
  • Girona, Mònica
  • Puighermanal Puigvert, Emma|||0000-0003-4271-9104
  • Appiah, Isabella|||0000-0002-4684-4992
  • Palmiter, Richard D.|||0000-0001-6587-0582
  • Sanz Iglesias, Elisenda|||0000-0002-7932-8556
  • Quintana Romero, Albert|||0000-0003-1674-7160
We live in an age where travel is paramount. However, one of the most disabling conditions inherent to traveling is motion sickness (MS). While studies have underscored the role of the vestibular system in the development of MS, the neuronal populations involved in motion-induced malaise remain largely unknown. Here, we describe the vestibular pathways eliciting MS responses and identify a key role for cholecystokinin (CCK)-expressing vestibular neurons. We reveal that a vestibulo-parabrachial (VN-PBN) CCKergic projection is sufficient to induce conditioned taste avoidance, likely through the activation of calcitonin gene-related peptide-expressing PBN neurons. Finally, we underscore the role of CCK-A receptor signaling as a druggable target to treat MS, providing insight on the neurobiological substrates of MS. Travel can induce motion sickness (MS) in susceptible individuals. MS is an evolutionary conserved mechanism caused by mismatches between motion-related sensory information and past visual and motion memory, triggering a malaise accompanied by hypolocomotion, hypothermia, hypophagia, and nausea. Vestibular nuclei (VN) are critical for the processing of movement input from the inner ear. Motion-induced activation of VN neurons recapitulates MS-related signs. However, the genetic identity of VN neurons mediating MS-related autonomic and aversive responses remains unknown. Here, we identify a central role of cholecystokinin (CCK)-expressing VN neurons in motion-induced malaise. Moreover, we show that CCK VN inputs onto the parabrachial nucleus activate Calca -expressing neurons and are sufficient to establish avoidance to novel food, which is prevented by CCK-A receptor antagonism. These observations provide greater insight into the neurobiological regulation of MS by identifying the neural substrates of MS and providing potential targets for treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dysfunctional LHX6 pallido-subthalamic projections mediate epileptic events in a mouse model of Leigh syndrome

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models

  • Puighermanal, Emma
  • Luna Sánchez, Marta
  • Gella, Alejandro
  • van der Walt, Gunter
  • Urpi, Andrea
  • Royo, María
  • Tena-Morraja, Paula
  • Appiah, Isabella
  • de Donato, María Helena
  • Menardy, Fabien
  • Bianchi, Patrizia
  • Esteve-Codina, Anna
  • Rodríguez-Pascau, Laura
  • Vergara, Cristina
  • Gómez-Pallarès, Mercè
  • Marsicano, Giovanni
  • Bellocchio, Luigi
  • Martinell, Marc
  • Sanz, Elisenda
  • Jurado, Sandra
  • Soriano, Francesc Xavier
  • Pizcueta, Pilar
  • Quintana, Albert
Mutations in mitochondrial energy-producing genes lead to a heterogeneous group of untreatable disorders known as primary mitochondrial diseases (MD). Leigh syndrome (LS) is the most common pediatric MD and is characterized by progressive neuromuscular affectation and premature death. Here, we show that daily cannabidiol (CBD) administration significantly extends lifespan and ameliorates pathology in two LS mouse models, and improves cellular function in fibroblasts from LS patients. CBD delays motor decline and neurodegenerative signs, improves social deficits and breathing abnormalities, decreases thermally induced seizures, and improves neuropathology in affected brain regions. Mechanistically, we identify peroxisome proliferator-activated receptor gamma (PPARγ) as a key nuclear receptor mediating CBD's beneficial effects, while also providing proof of dysregulated PPARγ expression and activity as a common feature in both mouse neurons and fibroblasts from LS patients. Taken together, our results provide the first evidence for CBD as a potential treatment for LS., This work was supported by three MINECO Ramon y Cajal fellowships (RYC2020-029596-I; E.P., RYC2019-028501-I; E.S., and RyC-2012-11873; A.Q.), a Beatriu de Pinós fellowship from University and Research Grants Catalan Management Agency (#2017BP00132; E.P.) Marie Sklodowska-Curie Individual Fellowship (H2020-MSCA-IF-2014-658352; E.S., H2020-MSCA-IF-2020-101030783, M.L-S., H2020-MSCA-COFUND-2014-665919, A.G.), pre-doctoral fellowships (2018FI_B 00452 to AU, 2024 FI-1 00645 to GvdW). E.P received funds from MICINN (PID2021-125079OA-I00). E.S received funds from MICIU Proyectos I + D + i “Retos Investigacion” (RTI2018-101838-J-I00) and Ministerio de Ciencia e Innovación (MICINN) (PID2019-107633RB-I00 and PID2022-142544OB-I00). A.Q. is a recipient of an ICREA Academia award and received funds from the European Research Council (Starting grant NEUROMITO, ERC-2014-StG-638106), Grants SAF2014-57981P; SAF2017-88108-R, PID2020-114977RB-I00, RTC2019-006825-1, PDC2021-121883-I0, RED2022-134786-T, funded by MICIU/AEI /10.13039/5011000110330 and by MICIU/AEI /10.13039/501100011033 and Next GenerationEU/ PRTR, AGAUR (2017SGR-323, 2021SGR-720), Fundació TV3-La Marató (202030), and “la Caixa” Foundation (ID 100010434), under the agreement LCF/PR/HR20/52400018., Peer reviewed